Edwards Lifesciences is sponsoring three educational symposia at STS 2024. Click on the calendar invitations below to add these events to your calendar and we'll see you there!

Visit Edwards at Booth #1409 at the 60^th STS Annual Meeting.

Making minimally invasive surgery maximally beneficial; Mitral valve replacement using an intra-aortic occlusion device

Saturday, January 27^th

9:10 AM - 9:40 AM CT

Exhibit Hall Theater 2

 

Add to calendar

How low can you go? Should mitral valve replacement age guidelines be lowered due to better bioprosthetic mitral valve durability?

Saturday, January 27^th

11:25 AM - 12:25 PM CT

Symposium, Room 217A

 

 

Add to calendar

The power of RESILIA tissue

COMMENCE trial seven-year BAV sub-analysis

Sunday, January 28^th

11:45 AM - 12:30 PM CT

Exhibit Hall Theater 2

 

Add to calendar

This industry symposia will be held in conjunction with the STS Annual Meeting. It is not part of the official STS scientific program. Continuing Medical Education (CME) credit for this activity is not offered by STS.

Important Safety Information: RESILIA Tissue Devices

 

Indications: INSPIRIS RESILIA Aortic Valve - For use in replacement of native or prosthetic aortic heart valves. KONECT RESILIA Aortic Valved Conduit - For use in replacement of native or prosthetic aortic heart valves and the associated repair or replacement of a damaged or diseased ascending aorta. MITRIS RESILIA Mitral Valve - For use in replacement of native or prosthetic mitral heart valves.

 

Contraindications: There are no known contraindications with the use of these RESILIA tissue heart valve devices.

 

Complications and Side Effects: INSPIRIS RESILIA Aortic Valve - Thromboembolism, valve thrombosis, hemorrhage, hemolysis, regurgitation, endocarditis, structural valve deterioration, nonstruc­tural dysfunction, stenosis, arrhythmia, transient ischemic attack/stroke, congestive heart failure, myocardial infarction, any of which could lead to reoperation, explantation, permanent disability, and death. Additional adverse events potentially associated with the use of polyester vascular grafts in the KONECT RESILIA AVC include hemorrhage, thrombosis, graft infection, embolism, aneurysm, pseudoaneurysm, seroma, occlusion (anastomotic intimal hyperplasia), immunological reaction to collagen (shown to be a weak immunogen; infrequent, mild, localized and self-limiting), intimal peel formation, and conduit dilatation. MITRIS RESILIA Mitral Valve - Thromboembolism, valve thrombosis, hemor­rhage, hemolysis, regurgitation, endocarditis, structural valve deterioration, nonstructural dysfunction, stenosis, arrhythmia, transient ischemic attack/stroke, congestive heart failure, myocardial infarction, ventricular perforation by stent posts, any of which could lead to reoperation, explantation, permanent disability, and death.

 

Warnings: INSPIRIS RESILIA Aortic Valve - DO NOT ADJUST THE VALVE DIAMETER BY EXPANDING THE BAND PRIOR TO OR DURING IMPLANTATION OF THE SURGICAL VALVE. The expandable band is not designed to allow for compression or expansion during implantation of the surgical valve. This will cause damage to the valve and may result in aortic incompetence. DO NOT PER­FORM STAND-ALONE BALLOON AORTIC VALVULOPLASTY PROCEDURES ON THIS VALVE FOR THE SIZES 19 – 25 mm as this may expand the valve causing aortic incompetence, coronary embolism or annular rupture. Valve-in-valve sizing in the INSPIRIS valve has only been tested with specific Edwards transcatheter heart valves. Use of other transcatheter valves may result in embolization of transcatheter devices anchored within or result in annular rupture.

 

CAUTION: Federal (USA) law restricts these devices to sale by or on the order of a physician. See Instructions for Use for full prescribing information.

Edwards, Edwards Lifesciences, the stylized E logo, COMMENCE, INSPIRIS, INSPIRIS RESILIA, KONECT, KONECT RESILIA, MITRIS, MITRIS RESILIA, and RESILIA are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2024 Edwards Lifesciences Corporation. All rights reserved. PP--US-9103  v1.0

 

Manage Preferences | Privacy Policy